Table 1 Patient characteristics by treatment.
Overall (N = 314) | Treatment group, N (%) | p-value | ||
|---|---|---|---|---|
HMAa (N = 148) | HMA + VEN (N = 166) | |||
Sex (male) | 186 (59) | 91 (61) | 95 (57) | 0.5 |
Age (years, median, range) | 73.7 (25.2, 89.6) | 74.0 (42.4, 88.5) | 73.7 (25.2, 89.6) | 0.4 |
Age categories (% within age group) | ||||
– <60 years | 32 (10) | 11 (7) | 21 (13) | 0.4 |
– 60 to <75 years | 152 (48) | 72 (49) | 80 (48) | >0.9 |
– ≥75 years | 130 (41) | 65 (44) | 65 (39) | 0.8 |
Prior MDS, MPN or MDS/MPN overlap | 111 (35) | 48 (32) | 63 (38) | 0.3 |
Prior myeloid disease directed therapy | ||||
– HMA | 35 (11) | 17 (11) | 18 (11) | 0.9 |
– Prior alloHCT | 29 (9) | 12 (8) | 17 (10) | 0.6 |
– t-AML | 87 (28) | 39 (26) | 48 (29) | 0.7 |
Cytogeneticsb | ||||
– Normal | 80 (29) | 38 (29) | 42 (29) | 0.9 |
– 5/7/17 abnormalities | 94 (34) | 47 (36) | 47 (32) | 0.4 |
– Complex karyotype | 116 (42) | 55 (43) | 61 (41) | >0.9 |
ELN 2022 risk stratification | ||||
– Favorable | 39 (12) | 15 (10) | 24 (14) | >0.9 |
– Intermediate | 40 (13) | 21 (14) | 19 (11) | >0.9 |
– Adverse | 235 (75) | 112 (76) | 123 (74) | 0.8 |
Ontogeny group | ||||
– De-novo | 88 (28) | 50 (34) | 38 (23) | 0.1 |
– Secondary | 115 (37) | 47 (32) | 68 (41) | 0.2 |
– TP53 | 111 (35) | 51 (34) | 60 (36) | 0.8 |
